Fussen Pharmaceutical (01652):. The marketing application for “metformin englicin tablets (I)” was submitted and accepted

Zhitong Finance ·  Apr 3 10:25

Zhitong Finance App News, Fussen Pharmaceutical (01652) announced that the “metformin englicin tablets (I)” developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the Group, has submitted a marketing application to the China National Drug Administration and has been accepted for the treatment of the following diseases: This product is used in combination with diet control and exercise, and is suitable for adult patients with type 2 diabetes who are being treated with engagliflozin and metformin hydrochloride to improve blood sugar control in these patients.

“Metformin Engagliflozin Tablets (I)” is a compound preparation composed of metformin hydrochloride and engagliflozin. The pharmacological effects are as follows: metformin can reduce hepatic glucose production, inhibit intestinal absorption of glucose, and increase peripheral tissue intake and utilization of glucose. It can increase insulin sensitivity by increasing the intake and utilization of peripheral sugar. Empagliflozin is an SGLT2 inhibitor. By reducing renal glucose reabsorption, lowering the renal sugar threshold, and promoting glucose excretion from urine, the two have a synergetic effect in terms of mechanism, and have a better hypoglycemic effect than ordinary monotherapy.

The National Health Commission of China announced the latest “China Medium- and Long-Term Plan for Chronic Disease Prevention and Control (2017-2025)”, which proposes the ultimate goal for 2025. The standard management rate and core knowledge awareness rate for diabetics must reach 70%, and the demand for diabetes medication will increase accordingly. Metformin englicin tablets (I) is a medical insurance class B variety. It has advantages such as good hypoglycemic effect, no serious adverse effects, and good patient tolerance. Bioequivalence tests on an empty stomach and after meals showed that the bioequivalence between this product and the original reference formulation was consistent. Metformin engagliptin tablets (I) provide a very favorable risk-benefit ratio in treating adult patients with type 2 diabetes in improving blood sugar control in these patients.

The director believes that metformin englicin tablets (I) is another important product of the Group, further enriching the Group's product pipeline in the field of diabetes treatment. After the product is launched, it will provide more treatment options for diabetics.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment